Eaton Vance Management’s Sarepta Therapeutics SRPT Stock Holding History

Eaton Vance Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$3.03M	Buy	27,375 +4,978	+22%	+$502K	﹤0.01%	917
2022 Q2	$1.68M	Buy	22,397 +6,009	+37%	+$442K	﹤0.01%	1131
2022 Q1	$1.28M	Buy	16,388 +16,060	+4,896%	+$1.23M	﹤0.01%	1306
2021 Q4	$30K	Hold	328	–	–	﹤0.01%	2281
2021 Q3	$0	Buy	+328	New	+$25.3K	﹤0.01%	2619
2021 Q2	–	Sell	-1,832	Closed	-$137K	–	3007
2021 Q1	$137K	Buy	+1,832	New	+$169K	﹤0.01%	1540
2019 Q3	–	Sell	-134,235	Closed	-$20.4M	–	1314
2019 Q2	$20.4M	Buy	134,235 +7	+0%	+$851	0.04%	302
2019 Q1	$16M	Buy	134,228 +22,454	+20%	+$2.89M	0.04%	323
2018 Q4	$12.2M	Buy	+111,774	New	+$14M	0.03%	331

Other funds holding SRPT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Eaton Vance Management's SRPT Position: Q3 2022 in Review

Eaton Vance Management increased its Sarepta Therapeutics (SRPT) stake by 22% in Q3 2022, buying an estimated $502K and bringing the position to 27,375 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #917.

Eaton Vance Management first reported a position in SRPT in Q4 2018 and has held it in 9 quarters since. The position peaked at $20.4M in Q2 2019. 375 funds tracked by Wall St. Rank hold SRPT as of Q3 2022.

Eaton Vance Management held 27,375 shares of Sarepta Therapeutics worth $3.03M as of Q3 2022.
Eaton Vance Management bought 4,978 Sarepta Therapeutics shares in Q3 2022, an estimated $502K.
Sarepta Therapeutics made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #917 holding.
Eaton Vance Management first reported a position in Sarepta Therapeutics in Q4 2018 and has held it in 9 quarters since.
Eaton Vance Management's Sarepta Therapeutics position peaked at $20.4M in Q2 2019.
375 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.